SLC13A5 and metabolic syndrome: Furthermore, the importance of citrate transport deficiency extends beyond patients with SLC13A5 Citrate Transporter Disorder, due to interest in developing liver specific NaCT inhibitors to treat metabolic syndrome and extending the lifespan [14,17,18,19,20,21,22].